Paper Details

  1. Home
  2. Paper Details

Inhaled iloprost as an add-on therapy for advanced pulmonary arterial hypertension: An Indian perspective.

Author: BobhatePrashant, GuptaRajat Kumar, KarandeTanuja, KulkarniSnehal

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study reports the benefits and difficulties of using inhaled iloprost in patients with advanced PAH in India, where prostacyclin analogues are not marketed. The study found that inhaled iloprost can be used with acceptable benefits and minimal side-effects in patients with PAH.
Paper Details　
Original Abstract of the Article :
Background Pulmonary arterial hypertension (PAH) is a progressive disease with high morbidity and mortality. Risk stratification and initiation of dual or triple combination therapy has a better clinical response, especially in high-risk patients. Unfortunately, prostacyclin analogues are not market...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.25259/NMJI_35_6_338

データ提供：米国国立医学図書館（NLM）

Inhaled Iloprost: A New Oasis in the Desert of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a challenging condition, a vast and unforgiving desert of symptoms and complications. This observational study, like a determined explorer seeking a cure, investigates the potential benefits of inhaled iloprost as an add-on therapy for patients with advanced PAH in India. The authors face the unique challenge of limited access to prostacyclin analogues in India, making inhaled iloprost a promising alternative. The study carefully evaluates the clinical, echocardiographic, and laboratory outcomes of 14 patients with PAH who received inhaled iloprost as an add-on therapy.

A Beacon of Hope in the Desert of PAH

The study's findings, like a shimmering oasis in the desert, reveal encouraging improvements in clinical parameters, including WHO functional class, right ventricular function, and NT-pro-BNP levels. The majority of patients experienced significant improvements in their overall health status. These results provide a beacon of hope for patients with advanced PAH, offering a potential treatment option that can improve their quality of life.

Navigating the Desert of Treatment Options

This study highlights the potential of inhaled iloprost as a valuable treatment option for patients with PAH, particularly in regions with limited access to other therapies. It emphasizes the importance of exploring alternative treatment approaches, especially in the face of limited resources. We must continue to navigate the desert of PAH research, seeking innovative solutions to improve the lives of those affected by this challenging condition.

Dr.Camel's Conclusion

This study offers a compelling case for the use of inhaled iloprost in patients with PAH, particularly in regions where other therapies may be limited. It provides a promising avenue for improving patient outcomes and highlights the importance of ongoing research to develop effective treatments for this challenging condition.

Date :
  1. Date Completed 2023-05-15
  2. Date Revised 2023-07-21
Further Info :

Pubmed ID

37167510

DOI: Digital Object Identifier

10.25259/NMJI_35_6_338

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.